Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.

Authors :: Chavana AN
Taylor ZL
DeGroote N
Lindsay HB
Sauer HE
Mason EJ
Schafer ES
Miller TP
Castellino SM
Pommert L
O'Brien MM
Ramsey LB
Bernhardt MB
Brown AL
Source :: Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Oct; Vol. 71 (10), pp. e31213. Date of Electronic Publication: 2024 Jul 22.
Publication Year :: 2024
Abstract: High-dose methotrexate (HD-MTX) is used in the treatment of children with central nervous system (CNS) tumors; however, toxicity information is limited. We characterized toxicities following 102 administrations of HD-MTX (4.6-13.5 g/m <superscript>2</superscript> ) infused over 4 or 24 h in 38 children with a CNS tumor before 6 years of age (2010-2020). Delayed clearance of methotrexate occurred following 24% of infusions. Common Terminology Criteria for Adverse Events v5 grade 2-3 mucositis was observed in 47% of individuals, Grade 4 neutropenia in 76%, and grade 3-4 thrombocytopenia in 58%. No neurotoxicity was observed. HD-MTX can be safely used with supportive care and monitoring.<br /> (© 2024 Wiley Periodicals LLC.)

Subjects :: Humans
Female
Male
Child, Preschool
Infant
Child
Follow-Up Studies
Retrospective Studies
Prognosis
Mucositis chemically induced
Neutropenia chemically induced
Methotrexate adverse effects
Methotrexate administration & dosage
Central Nervous System Neoplasms drug therapy
Antimetabolites, Antineoplastic adverse effects
Antimetabolites, Antineoplastic administration & dosage

Full Text Access

Tools